Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Guidance for MD Studies Completed
June 23, 2008
- Great Variability Seen in Clinical Data Packages Submitted for Applications in Japan: OPIR
June 23, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF -2-
June 23, 2008
- R&D NEWS IN BRIEF -1-
June 23, 2008
- Otsuka, UCB Tie Up for Keppra and Cimzia in Japan
June 23, 2008
- R&D NEWS IN BRIEF -2-
June 23, 2008
- Asahi Kasei Pharma Licenses Treatment for Osteoarthritis
June 23, 2008
- MEDICAL DEVICE NEWS IN BRIEF
June 23, 2008
- Pfizer Beefs Up Promotion of Norvasc
June 23, 2008
- SELF-MEDICATION NEWS IN BRIEF
June 23, 2008
- Diovan Stays No. 1 for 3 Months in a Row: Rep Track Survey
June 23, 2008
- SEMINARS
June 23, 2008
- BUSINESS NEWS IN BRIEF
June 23, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF -1-
June 23, 2008
- Yamato HD Proposes Direct Deal between Makers and Med. Institutions
June 23, 2008
- Daiichi Sankyo to Acquire Majority of Ranbaxy Shares
June 23, 2008
- Increase Share of Generics to 40%: Council
June 23, 2008
- GENERICS NEWS IN BRIEF
June 23, 2008
- FPMAJ Report on FY2008 NHI Price Revision
June 23, 2008
- Lurasidone Holds Key to DSP's Success in Global Business Development: Mr Tada
June 16, 2008
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…